Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, protein-synthesis inhibitors, tetracycline derivatives | 2661 | 220620-09-7 |
Dose | Unit | Route |
---|---|---|
0.10 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 295 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 22 % | Benet LZ, Broccatelli F, Oprea TI |
BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 12 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 3.80 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.20 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 48 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
June 15, 2005 | FDA | PF PRISM CV |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pathogen resistance | 213.72 | 30.77 | 56 | 3493 | 6004 | 46676509 |
Pancreatitis acute | 146.35 | 30.77 | 59 | 3490 | 24813 | 46657700 |
Pancreatitis | 120.42 | 30.77 | 61 | 3488 | 43566 | 46638947 |
Drug resistance | 97.97 | 30.77 | 40 | 3509 | 17328 | 46665185 |
Klebsiella infection | 80.96 | 30.77 | 27 | 3522 | 6635 | 46675878 |
Thrombocytopenia | 63.52 | 30.77 | 62 | 3487 | 126519 | 46555994 |
Hypofibrinogenaemia | 63.37 | 30.77 | 15 | 3534 | 1055 | 46681458 |
Acinetobacter infection | 59.13 | 30.77 | 15 | 3534 | 1407 | 46681106 |
Multiple organ dysfunction syndrome | 56.92 | 30.77 | 40 | 3509 | 51670 | 46630843 |
Sepsis | 47.55 | 30.77 | 55 | 3494 | 135959 | 46546554 |
Adjusted calcium decreased | 46.64 | 30.77 | 8 | 3541 | 106 | 46682407 |
Septic shock | 44.20 | 30.77 | 36 | 3513 | 57857 | 46624656 |
Biloma | 43.59 | 30.77 | 7 | 3542 | 60 | 46682453 |
Globulins decreased | 41.57 | 30.77 | 8 | 3541 | 207 | 46682306 |
Haemodynamic instability | 40.84 | 30.77 | 17 | 3532 | 7708 | 46674805 |
Morganella infection | 40.81 | 30.77 | 9 | 3540 | 461 | 46682052 |
Haemostasis | 40.50 | 30.77 | 8 | 3541 | 238 | 46682275 |
Systemic inflammatory response syndrome | 39.50 | 30.77 | 15 | 3534 | 5356 | 46677157 |
Hepatotoxicity | 38.82 | 30.77 | 24 | 3525 | 24985 | 46657528 |
Coma hepatic | 38.39 | 30.77 | 9 | 3540 | 607 | 46681906 |
Drug ineffective | 38.08 | 30.77 | 125 | 3424 | 677713 | 46004800 |
Multiple-drug resistance | 37.65 | 30.77 | 12 | 3537 | 2553 | 46679960 |
Immunosuppressant drug level increased | 34.75 | 30.77 | 12 | 3537 | 3270 | 46679243 |
Escherichia infection | 32.35 | 30.77 | 16 | 3533 | 10801 | 46671712 |
Blood fibrinogen decreased | 32.05 | 30.77 | 8 | 3541 | 702 | 46681811 |
Nephropathy toxic | 31.49 | 30.77 | 14 | 3535 | 7440 | 46675073 |
Wound haemorrhage | 31.42 | 30.77 | 10 | 3539 | 2117 | 46680396 |
Blood urea increased | 31.14 | 30.77 | 21 | 3528 | 25331 | 46657182 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pathogen resistance | 165.23 | 25.22 | 58 | 4468 | 8352 | 29939600 |
Hypofibrinogenaemia | 143.51 | 25.22 | 36 | 4490 | 1609 | 29946343 |
Septic shock | 135.38 | 25.22 | 96 | 4430 | 63511 | 29884441 |
Drug ineffective | 126.93 | 25.22 | 201 | 4325 | 340186 | 29607766 |
Multiple organ dysfunction syndrome | 93.47 | 25.22 | 77 | 4449 | 63410 | 29884542 |
Drug resistance | 93.26 | 25.22 | 50 | 4476 | 20083 | 29927869 |
Enterococcal infection | 76.57 | 25.22 | 33 | 4493 | 8191 | 29939761 |
Klebsiella infection | 71.97 | 25.22 | 30 | 4496 | 6857 | 29941095 |
Mycobacterium chelonae infection | 66.76 | 25.22 | 16 | 4510 | 589 | 29947363 |
Sepsis | 60.35 | 25.22 | 91 | 4435 | 146304 | 29801648 |
Treatment failure | 55.03 | 25.22 | 44 | 4482 | 34635 | 29913317 |
Thrombocytopenia | 54.78 | 25.22 | 84 | 4442 | 136960 | 29810992 |
Pancreatitis acute | 50.42 | 25.22 | 37 | 4489 | 25658 | 29922294 |
Ototoxicity | 49.20 | 25.22 | 15 | 4511 | 1381 | 29946571 |
Pancreatitis | 46.91 | 25.22 | 41 | 4485 | 36449 | 29911503 |
Mycobacterium abscessus infection | 42.11 | 25.22 | 11 | 4515 | 577 | 29947375 |
Acinetobacter infection | 40.55 | 25.22 | 12 | 4514 | 998 | 29946954 |
Klebsiella bacteraemia | 40.01 | 25.22 | 12 | 4514 | 1045 | 29946907 |
Multiple-drug resistance | 38.25 | 25.22 | 15 | 4511 | 2926 | 29945026 |
Gallstone ileus | 37.55 | 25.22 | 6 | 4520 | 22 | 29947930 |
Coagulopathy | 34.85 | 25.22 | 26 | 4500 | 18461 | 29929491 |
Fungaemia | 31.22 | 25.22 | 12 | 4514 | 2219 | 29945733 |
Deafness neurosensory | 30.40 | 25.22 | 12 | 4514 | 2381 | 29945571 |
Anuria | 30.10 | 25.22 | 19 | 4507 | 10297 | 29937655 |
Flavobacterium infection | 29.98 | 25.22 | 6 | 4520 | 93 | 29947859 |
Candida infection | 29.84 | 25.22 | 22 | 4504 | 15340 | 29932612 |
Product use in unapproved indication | 29.11 | 25.22 | 45 | 4481 | 73648 | 29874304 |
Haematological malignancy | 29.04 | 25.22 | 6 | 4520 | 110 | 29947842 |
Acoustic neuroma | 27.91 | 25.22 | 6 | 4520 | 134 | 29947818 |
Staphylococcal infection | 27.40 | 25.22 | 28 | 4498 | 30196 | 29917756 |
Bacteraemia | 27.37 | 25.22 | 21 | 4505 | 15539 | 29932413 |
Hepatotoxicity | 26.60 | 25.22 | 22 | 4504 | 18123 | 29929829 |
Nausea | 25.35 | 25.22 | 100 | 4426 | 296857 | 29651095 |
Source | Code | Description |
---|---|---|
ATC | J01AA12 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE TETRACYCLINES Tetracyclines |
FDA CS | M0021223 | Tetracyclines |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D011500 | Protein Synthesis Inhibitors |
FDA EPC | N0000175938 | Tetracycline-class Antibacterial |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Pneumonia due to Streptococcus | indication | 34020007 | |
Haemophilus influenzae pneumonia | indication | 70036007 | |
Abdominal abscess | indication | 75100008 | |
Infectious disease of abdomen | indication | 128070006 | |
Complicated appendicitis | indication | 418171008 | |
Complicated Skin and Skin Structure E. Coli Infection | indication | ||
Complicated Skin and Skin Structure Staphylococcus Aureus Infection | indication | ||
Complicated Skin and Skin Structure Infection | indication | ||
Complicated Skin and Skin Structure Streptococcus Pyogenes Infection | indication | ||
Legionella Pneumophila Pneumonia | indication | ||
Complicated Bacterial Peritonitis | indication | ||
Complicated Skin and Skin Structure Enterococcus Faecalis Infection | indication | ||
Complicated Skin and Skin Structure Streptococcus Agalactiae Infection | indication | ||
Hyperbilirubinemia | contraindication | 14783006 | DOID:2741 |
Gastrointestinal perforation | contraindication | 51875005 | |
Hepatic failure | contraindication | 59927004 | |
Pancreatitis | contraindication | 75694006 | DOID:4989 |
Pregnancy, function | contraindication | 289908002 | |
Pseudomembranous enterocolitis | contraindication | 397683000 | |
Antibiotic-Induced Hypoprothrombinemia | contraindication |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 3.13 | acidic |
pKa2 | 8.64 | acidic |
pKa3 | 11.14 | acidic |
pKa4 | 11.96 | acidic |
pKa5 | 13.08 | acidic |
pKa6 | 13.93 | acidic |
pKa7 | 9.41 | Basic |
pKa8 | 7.96 | Basic |
pKa9 | 7.31 | Basic |
None
None
None
ID | Source |
---|---|
4024922 | VUID |
N0000171604 | NUI |
D01079 | KEGG_DRUG |
4024922 | VANDF |
C0255348 | UMLSCUI |
CHEBI:142708 | CHEBI |
T1C | PDB_CHEM_ID |
CHEMBL376140 | ChEMBL_ID |
D000078304 | MESH_DESCRIPTOR_UI |
C087533 | MESH_SUPPLEMENTAL_RECORD_UI |
54686193 | PUBCHEM_CID |
8115 | INN_ID |
DB00560 | DRUGBANK_ID |
70JE2N95KR | UNII |
10929 | IUPHAR_LIGAND_ID |
384455 | RXNORM |
20166 | MMSL |
230306 | MMSL |
69774 | MMSL |
d05537 | MMSL |
010833 | NDDF |
418313005 | SNOMEDCT_US |
418631002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Tygacil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0008-4990 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | NDA | 33 sections |
Tygacil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0008-4994 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | NDA | 30 sections |
Tigecycline | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3481 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 26 sections |
TIGECYCLINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-364 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | NDA | 31 sections |
Tigecycline | Human Prescription Drug Label | 1 | 55150-228 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 28 sections |
Tigecycline | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-6098 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 27 sections |
Tigecycline | Human Prescription Drug Label | 1 | 63323-960 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | NDA | 27 sections |
Tigecycline | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70121-1647 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | NDA | 22 sections |
Tigecycline | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70594-035 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 33 sections |
Tigecycline | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-019 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 30 sections |